Hector Esquer

University of Colorado Anschutz Medical Campus

ORCID: 0000-0002-1911-1523

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 9 papers. Top paper: “First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer”.

First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer

Molecular Cancer Therapeutics(2020)10.1158/1535-7163.mct-20-0106

N/A

0.510DataRank · unranked

29 citations

Qiong Zhou, Hector Esquer, Laura A. Pike, Travis P. Broneske, Sébastien Rinaldetti +10 more

High-Content Drug Discovery Targeting Molecular Bladder Cancer Subtypes

International Journal of Molecular Sciences(2022)10.3390/ijms231810605

N/A

0DataRank · unranked

6 citations

Qiong Zhou, Joshua M. Abbott, Florus C. de Jong, Hector Esquer, James C. Costello +3 more

The validation of new CHD1L inhibitors as a therapeutic strategy for cancer

Biomedicine & Pharmacotherapy(2023)10.1016/j.biopha.2023.116037

N/A

0DataRank · unranked

8 citations

Paul Awolade, Qiong Zhou, Hector Esquer, Brock Matter, J. Kearns +5 more

HTS discovery of PARP1-HPF1 complex inhibitors in cancer

SLAS DISCOVERY(2023)10.1016/j.slasd.2023.10.003

N/A

0DataRank · unranked

7 citations

Rida Noor, Qiong Zhou, Hector Esquer, Rita Sala, Petra Stojanovic +4 more

CHD1L Regulates Cell Survival in Breast Cancer and Its Inhibition by OTI-611 Impedes the DNA Damage Response and Induces PARthanatos

International Journal of Molecular Sciences(2024)10.3390/ijms25168590

N/A

0DataRank · unranked

6 citations

Hector Esquer, Timothy Kellett, J. Kearns, Paul Awolade, Qiong Zhou +2 more

CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models

International Journal of Molecular Sciences(2024)10.3390/ijms252313160

N/A

0DataRank · unranked

5 citations

Hector Esquer, Timothy Kellett, Sophia Clune, Paul Awolade, Laura A. Pike +4 more

Targeted Inhibition of CHD1L by OTI-611 Reprograms Chemotherapy and Targeted Therapy-Induced Cell Cycle Arrest and Suppresses Proliferation to Produce Synergistic Antitumor Effects in Breast and Colorectal Cancer

Cells(2025)10.3390/cells14050318

N/A

0DataRank · unranked

7 citations

Qiong Zhou, Daniel V. LaBarbera, Hector Esquer

CHD1L in cancer and beyond: structure, oncogenic functions, and therapeutic potential

Journal of Experimental & Clinical Cancer Research(2025)10.1186/s13046-025-03428-1

N/A

0DataRank · unranked

2 citations

Paul Awolade, Hector Esquer, Qiong Zhou, Daniel V. LaBarbera, Sophia Clune

Breast cancer cell coculture induces normal lung fibroblast transition to CAFs, promoting tumor cell dormancy and therapy resistance

Proceedings of the National Academy of Sciences(2025)10.1073/pnas.2423894122

N/A

0DataRank · unranked

1 citations

Kathryn E. Cronise, Eric P. Palmer, Kelly McAuliffe, Claire Stratton, Kathryn E. Sparks +7 more